Int J Pharm Pharm Sci, Vol 18, Issue 1, 14-22Review Article

RESVERATROL: A MULTIFACETED NATURAL COMPOUND WITH THERAPEUTIC POTENTIAL

LALIT P. DEWALKAR*

Department of Zoology Guru Nanak College of Science, Ballarpur-442701, Maharashtra, India
*Corresponding author: Lalit P. Dewalkar; *Email: lalit.dewalkar@gncolleg.co.in

Received: 07 Oct 2025, Revised and Accepted: 17 Nov 2025

ABSTRAC

Resveratrol, a plant-derived polyphenol abundant in grapes, berries, peanuts, and red wine, has been the subject of intense scientific exploration for more than three decades. First associated with the French Paradox, it is now widely studied for its ability to influence multiple biological pathways that underlie chronic disease and aging. Experimental evidence shows that resveratrol reduces oxidative stress, modulates inflammatory cascades, improves mitochondrial function, and regulates cell survival and metabolism. Through these actions, it exerts antioxidant, anti-inflammatory, cardioprotective, anticancer, neuroprotective, antidiabetic, hepatoprotective, antimicrobial, and anti-aging effects. While laboratory and animal studies provide compelling support, outcomes from human trials remain variable, reflecting challenges such as poor bioavailability, rapid metabolism, and differences in study design. Recent innovations including nanoparticle based carriers, synthetic analogs, and synergistic formulations are being developed to enhance its stability and clinical utility. Resveratrol is not a miracle cure, but rather a promising candidate for adjunct therapy, underscoring the potential of natural compounds to complement conventional medicine pending further clinical validation. Its journey underscores the need for rigorous, long-term, and well controlled clinical studies to establish effective doses, safety profiles, and therapeutic applications. By bridging traditional phytotherapy and modern translational science, resveratrol continues to inspire both researchers and clinicians in the search for holistic approaches to health and disease management.

Keywords: Resveratrol, Polyphenol, Antioxidant, Cardioprotection, Neuroprotection, Anticancer, Anti-inflammatory, Anti-aging, Bioavailability

© 2026 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (https://creativecommons.org/licenses/by/4.0/)
DOI: https://dx.doi.org/10.22159/ijpps.2026v18i1.57113 Journal homepage: https://innovareacademics.in/journals/index.php/ijpps

INTRODUCTION

Resveratrol (3,5,4’-trihydroxy-trans-stilbene) is a naturally occurring phytoalexin from the stilbene family of polyphenols. Plants synthesize it as a protective response to environmental stressors such as ultraviolet (UV) radiation, microbial infection, or physical injury. The compound was first identified in the 1940s from Veratrum grandiflorum and later from the roots of Polygonum cuspidatum, a plant still widely used as a commercial source [1]. Resveratrol entered the scientific spotlight in the early 1990s when its presence in red wine was linked to the French paradox in which the observation that French populations had relatively low rates of cardiovascular disease despite diets rich in saturated fat [2]. Since then, it has become a central point of research, extending far beyond heart health to potential benefits in cancer prevention, neuroprotection, metabolic regulation, and healthy aging.

From a chemical perspective, resveratrol occurs in two structural forms-trans and cis isomers, with the trans-form being both more stable and biologically active [3]. This compound is remarkably versatile, interacting with a broad range of molecular targets that include signaling cascades and transcription factors [4]. Through these interactions, resveratrol influences key cellular processes such as oxidative stress regulation, inflammatory signaling, mitochondrial biogenesis, cell proliferation, and programmed cell death [5–8]. Because of this pleiotropic activity, resveratrol has attracted interest as a potential therapeutic agent for several chronic conditions, including cardiovascular disease, diabetes, cancer, neurodegenerative disorders, osteoporosis, and hepatic and renal dysfunction.

Despite the wealth of promising preclinical data, translating resveratrol’s benefits into clinical practice has proven difficult. One of the major barriers is its pharmacokinetic profile: resveratrol has poor water solubility, undergoes rapid metabolism, and shows very low systemic bioavailability following oral administration [9–11]. These limitations significantly reduce its therapeutic effectiveness in humans. To overcome these hurdles, researchers have been actively exploring advanced delivery strategies, including nanoparticle-based carriers, liposomal formulations, and synthetic analogs designed to improve stability, absorption, and tissue targeting [12–14].

Literature search strategy

To ensure a comprehensive and unbiased overview, a thorough search of the scientific literature was conducted using the PubMed, Scopus, and Web of Science databases. The search spanned the years 2000 to 2025 and combined key terms such as “resveratrol,” “NAD⁺ metabolism,” “SIRT1,” “oxidative stress,” “inflammation,” “clinical trials,” “pharmacokinetics,” and “disease prevention.” This review article focused on peer-reviewed research articles, reviews, and clinical studies published in English, giving preference to recent work that offered clear mechanistic or translational insight. Additional relevant sources were identified by manually cross-checking references from key publications. This approach ensured that the review reflects the most current and balanced understanding of resveratrol’s biological and clinical potential.

Natural sources of resveratrol

Resveratrol is found in a variety of foods and medicinal plants, though its levels vary widely depending on species, cultivation, and processing. Grapes and red wine are the best-known sources, with higher concentrations in grape skins, seeds, and stems. Berries such as blueberries, cranberries, and mulberries, along with peanuts and peanut products, also contribute to dietary intake, with boiling shown to enhance resveratrol levels in peanuts. Among medicinal plants, Polygonum cuspidatum (Japanese knotweed) is the richest natural source and is widely used for supplement production [15–18]. Environmental factors such as UV exposure, pathogen attack, and post-harvest storage further influence resveratrol content, highlighting the variability of its dietary availability [19].

Safety and tolerable dose

The safety profile of resveratrol in humans has been assessed in a limited number of clinical trials, and while findings are encouraging, long-term tolerability data remain scarce. In a 29 d randomized study involving 44 healthy volunteers, participants received escalating doses of 500, 1000, 2500, and 5000 mg/d of RES. Mild gastrointestinal disturbances, including nausea, diarrhea, and abdominal discomfort, were reported primarily at doses exceeding 1000 mg/d [31]. Similarly, another trial administering 1000 mg/d of RES to healthy adults found the compound to be generally safe, with only mild and transient adverse effects [32].

Evidence from longer-term supplementation is limited but noteworthy. In a one-year study, daily intake of grape-derived RES at a relatively low dose of 8 mg/d was associated with improved cardiovascular risk profiles, without significant adverse events [33]. Overall, available data suggest that resveratrol is well tolerated at low to moderate doses, with gastrointestinal discomfort being the most frequent side effect at higher intakes. However, no official safe upper limit or Tolerable Upper Intake Level (UL) has been established by major regulatory agencies such as the U. S. Food and Drug Administration (FDA) or the European Food Safety Authority (EFSA). However, more comprehensive and long-term clinical trials are necessary to fully establish itssafety profile across diverse populations.

Table 1: Natural sources of resveratrol and approximate content

Source Plant part/Sample type Total resveratrol content (µg/g) Notes Reference
Red Grape Skin 0.03-29.5 Found mainly as trans-resveratrol; varies by cultivar and season (highest in Pinot Noir, Feteasca Neagra, lowest in Mamaia) [20]
Red wine Fermented beverage 0.3-7.0* It depends on the cultivar of the grape from which red wine is derived. Lowest from Cabernet Sauvignon and highest from Pinot Noir [20, 21]
Grape Resin Dried skin 1-80 Highest in Black Bordeaux (red grape), lowest in Torontel (white grape) cultivar [22]
Dark chocolate Processed product 0.3-0.5 The concentration of resveratrol is influenced by the cocoa content. [23]
Tomato Whole fruit 1-100 Transgenic tomato developed by inserting grapevine stilbene synthase gene produced high amount of resveratrol than that of wild variety. The tomato lineLoxS produced lowest resveratrol and 35SS produced highest concentration of resveratrol at ripening stage. [24]
Apples Skin 0.67 The lowest concentration reported in the Golden Delicious variety (green apple), while the highest concentration is found in the Bravo de Esmolfe variety (red apple). The resveratrol content is influenced by postharvest stress and pigmentation levels. [25–28]
Mulberry Whole fruit 50.61 [29]
Java plum (Syzygiumcumini) seed Seed 34.87 Detected via HPLC; mostly trans-resveratrol form. [29]
Japanese knotweed (Polygonum cuspidatum) root extract Root extract 0.23–3,140 Concentration of total resveratrol depends on plant part, geographical region and season. Stem of Polygonum cuspidatum from Kagami region of Japan contains lowest resveratrol, whereas during summer season it contains highest resveratrol (3140 µg/g) [15]
Itadori tea (Polygonum cuspidatum) Stem 0.46* Sunlight, rainfall, and insect damage influence resveratrol levels. [30]

*For liquids like wine and tea, concentrations are reported as µg/ml; conversion to µg/g is approximate for comparison only. Assuming the density of wine and tea is close to water (1 g/ml), I have convert mg/l to µg/g using: 1 mg/l=1 µg/g

Table 2: Biological activities of resveratrol: mechanisms and representative references

Biological activity Primary mechanisms/targets Typical readouts/models References
Antioxidant Direct ROS/RNS scavenging; metal chelation; activation of Nrf2 leads to upregulation of HO-1, NQO1, SOD, GPx; mitochondrial ROS lowering via SIRT1/AMPK–PGC-1α axis. Lowers MDA, promotes GSH, SOD, catalase, GPx activity; improved mitochondrial respiration [6, 36–39]
Anti-inflammatory Inhibition of NF-κB, STAT3, COX-2, iNOS; lowers IL-6, TNF-α Lowers CRP and cytokines in cell, animal, and clinical models [33, 40–42]
Cardioprotective Promotes eNOS/NO bioavailability; lowers LDL oxidation; lowers platelet aggregation; improved mitochondrial efficiency via SIRT1/AMPK Improved endothelial function, BP, lipid profile, infarct reduction [43–46]
Anticancer Cell cycle arrest, apoptosis (p53/caspases); inhibition of NF-κB, PI3K/Akt, Wnt/β-catenin, MAPK; suppression of EMT/MMP; autophagy/dormancy induction Lowers tumor growth, invasion, metastasis; promotes apoptosis; lowers proliferation in multiple cancer models [47–51]
Metabolic/Antidiabetic AMPK/SIRT1 activation; improved insulin signaling; anti-inflammatory adipokine modulation Improved glucose tolerance, lowers HOMA-IR, lipid profile changes [34, 51–54]
Hepatoprotective (NAFLD/NASH) Antioxidant and anti-inflammatory actions; lipid handling; mitochondrial regulation Lowers ALT/AST, lowers hepatic fat, improved histology. [55–58]
Neuroprotective/Anti-aging SIRT1/AMPK–PGC-1α activation; antioxidant (Nrf2); anti-amyloid/tau aggregation; improved cerebral blood flow Promotes Memory/cognition; lowers Aβ/tau pathology; promotes CBF in human studies [59–62]
Bone/Osteoprotective Promotes osteoblast activity; lowers osteoclastogenesis; anti-inflammatory via NF-κB inhibition Promotes bone mineral density; improved biomechanics [63, 64]
Antimicrobial/Antiviral Interference with quorum sensing, bacterial membranes, viral replication inhibition Lowers bacterial growth and viral replication (HSV, influenza) [65, 66]
Dermatologic/Photoprotection Antioxidant and anti-inflammatory; MMP inhibition Lowers UV-induced skin damage, lowers MMP-1 [67, 68]
Renal/Organ protection Anti-oxidative and anti-fibrotic effects; SIRT1-mediated mitochondrial protection Lowers AKI, CKD progression, lowers fibrosis markers [69]

Clinical applications and challenges

Though laboratory studies consistently demonstrate the strong therapeutic promise of resveratrol, results from human clinical trials have been far less consistent [34]. One of the main challenges lies in its pharmacokinetics, resveratrol is poorly absorbed, rapidly metabolized, and achieves only low circulating levels after ingestion [9]. To address these limitations, researchers are actively exploring innovative strategies, including nanoparticle based delivery systems, the development of more stable structural analogs, and synergistic formulations with other bioactive compounds. These approaches aim to improve bioavailability and, ultimately, enhance the clinical efficacy of resveratrol [35].

Antioxidant activity

Resveratrol protects against oxidative stress through both direct and indirect mechanisms. It directly scavenges reactive oxygen/nitrogen species and chelates transition metals, thereby reducing lipid peroxidation and even influencing iron-dependent cell death pathways such as ferroptosis [70–72]. More importantly, it enhances endogenous defenses by activating Nrf2 signaling, leading to upregulation of antioxidant enzymes including superoxide dismutase (SOD), catalase, glutathione peroxidase, and phase II detoxifying enzymes like HO-1 and NQO1 [37, 73]. In parallel, resveratrol modulates mitochondrial function through the SIRT1/AMPK–PGC-1α pathway, improving oxidative phosphorylation and reducing mitochondrial ROS production [74–76]. These mechanisms collectively place resveratrol as a key regulator of redox homeostasis across different experimental models.

Evidence from animal and cell studies is strong, but human trials show more variable outcomes. Meta-analyses suggest modest improvements in oxidative stress and inflammatory biomarkers such as TNF-α and high-sensitivity C-reactive protein (hs-CRP), although results vary by dose, formulation, duration and study population [53, 77]. Poor bioavailability and rapid metabolism are major barriers, fueling research into advanced delivery strategies such as nanoparticle formulations, structural analogs, and hybrid molecules with enhanced stability and metal-chelating properties [78, 79].

Notably, resveratrol can act as a pro-oxidant under certain conditions, particularly at high concentrations or in metal-rich environments [72]. The pro-oxidant activity of resveratrol is notably amplified in the presence of transition metals. Copper-resveratrol interactions generate ROS through Fenton-like reactions. The mechanism involves resveratrol reducing Cu²⁺ to Cu⁺, which leads to the generation of ROS. This is similar to a Fenton-like reaction, although the article doesn't use that exact term [80]. In another study, plasmid DNA (pBR322) used as a model system, the researchers observed that resveratrol, in combination with Cu²⁺, caused significant DNA strand breaks and mutagenic lesions, as evidenced by electrophoretic mobility shifts. The underlying mechanism was attributed to the reduction of Cu²⁺ to Cu⁺ by resveratrol, leading to the generation of reactive oxygen species (ROS) such as hydroxyl radicals, which attack DNA bases and the sugar-phosphate backbone [81]. This paradoxical activity may contribute to its chemopreventive potential, as moderate ROS generation can trigger selective apoptosis in premalignant or cancerous cells [82]. However, these same mechanisms also highlight the importance of dose control, since excessive or chronic oxidative stress may lead to cellular toxicity. Overall, although resveratrol is not a universal antioxidant remedy, its dual antioxidant and pro-oxidant capacities when properly contextualized make it a promising adjunct for redox modulation and cancer prevention, provided dosing and biological context are carefully managed.

Cardioprotective activity

Resveratrol is increasingly appreciated for its cardioprotective effects, which arise from its ability to counter oxidative stress, dampen inflammation, and support healthy vascular function. A key mechanism involves the stimulation of endothelial nitric oxide synthase (eNOS), leading to greater nitric oxide (NO) availability. This not only promotes vascular relaxation and improved blood flow but also contributes to the regulation of blood pressure and protection against hypertension [43, 83]. Through the activation of the SIRT1/AMPK signaling pathways, resveratrol enhances mitochondrial efficiency, curbs oxidative stress, and supports stable cardiac energy metabolism. By sustaining mitochondrial health, it helps the heart adapt to metabolic stress and maintain optimal function under both physiological and pathological conditions [76, 84]. Resveratrol also counters vascular inflammation by suppressing NF-κB signaling and downregulating the expression of adhesion molecules. This action reduces endothelial activation and leukocyte recruitment, thereby limiting the initiation and progression of atherosclerotic lesions [85]. Experimental evidence also highlights resveratrol’s ability to lower LDL oxidation, inhibit platelet aggregation, and preserve endothelial progenitor cell function, mechanisms that work together to maintain vascular integrity and reduce the risk of cardiovascular events.

Clinical evidence, though somewhat heterogeneous, indicates that resveratrol supplementation may lead to modest improvements in blood pressure, lipid metabolism, and vascular reactivity, particularly in individuals at elevated cardiovascular risk [44, 86]. However, the clinical outcomes remain inconsistent, largely because of variations in dosage, formulation, and the inherently low bioavailability of resveratrol, challenges that are common to many natural compounds under investigation. To overcome these barriers, researchers are exploring novel delivery approaches such as nanoparticle formulations, structural analogs, and synergistic combinations with other bioactive to enhance its cardiovascular efficacy. Taken together, the current body of evidence supports resveratrol as a promising adjunctive strategy for cardiovascular health, but its translation into routine practice will require large-scale, long-term clinical trials to confirm safety, efficacy, and optimal therapeutic protocols.

Anticancer activity

Resveratrol shows considerable promise as an anticancer agent because it can act on several hallmarks of cancer simultaneously. It helps protect the cells from key drivers of tumor initiation. At the same time, it can trigger cell cycle arrest and apoptosis through activation of tumor suppressors such as p53 and caspases, while blocking major growth and survival pathways including NF-κB, PI3K/Akt, Wnt/β-catenin, and MAPK [47, 48, 87]. Recent studies demonstrate that resveratrol can also impede tumor invasion and metastasis by blocking epithelial-to-mesenchymal transition (EMT) and downregulating matrix metalloproteinases (MMPs). Furthermore, it promotes autophagy-associated tumor dormancy, maintaining malignant cells in a quiescent, non-proliferative state and thereby slowing disease progression [88-90]. Notably, under certain conditions, particularly in the presence of transition metals such as copper-resveratrol may display controlled pro-oxidant activity, contributing to selective apoptosis in premalignant or cancerous cells, a mechanism proposed to support its chemopreventive potential [82].

Extensive preclinical studies across various cancer models, including breast, prostate, colon, lung, and oral cancers, consistently support these antitumor mechanisms. Early human trials indicate that resveratrol is well tolerated and can modulate biomarkers of tumor growth and proliferation [91, 92]. However, these biomarker changes rarely translate into measurable tumor regression or survival benefits in human subjects, underscoring the gap between preclinical promise and clinical efficacy. Limitations related to poor bioavailability, rapid metabolism, and heterogeneous dosing regimens continue to hinder therapeutic translation. To address these challenges, current research focuses on advanced formulations, including nanoparticle delivery systems, synthetic analogs, and synergistic combinations with existing chemotherapies, aimed at improving systemic exposure and clinical outcomes [93, 94].

Anti-aging activity

Resveratrol has been widely studied for its potential anti-aging properties, largely because it influences molecular pathways that regulate longevity, stress resistance, and metabolic health (table 3). One of its most well-characterized effects is the activation of sirtuin 1 (SIRT1), a key NAD⁺-dependent deacetylase involved in DNA repair, mitochondrial biogenesis, and metabolic regulation [6, 36]. By enhancing SIRT1 activity and interacting with AMPK and PGC-1α signaling, resveratrol helps improve mitochondrial efficiency, reduce oxidative stress, and support cellular energy balance all of which are central to slowing age-related decline [76, 95].

Beyond cellular metabolism, resveratrol combats chronic low-grade inflammation by downregulating NF-κB activity and reducing the production of pro-inflammatory cytokines [40]. It also activates Nrf2-dependent antioxidant defenses, thereby protecting cells from oxidative damage, one of the primary drivers of aging [96]. Animal studies show that resveratrol can extend lifespan in lower organisms and improve health span markers in mammals, including vascular function, glucose metabolism, and cognitive performance [6, 97]. Human trials are more limited and heterogeneous but suggest modest benefits for metabolic health, vascular function, and inflammatory biomarkers, especially in older or at-risk populations [55, 98, 99]. While not a miracle ‘longevity pill,’ resveratrol remains one of the most promising natural compounds for supporting healthy aging, with ongoing research into optimized formulations to improve its bioavailability and clinical efficacy.

Table 3: Anti-aging mechanisms and evidence of resveratrol

Mechanism Preclinical evidence Human evidence References
SIRT1 activation and AMPK–PGC-1α signaling Extends lifespan in yeast, worms, and flies; improves mitochondrial biogenesis and energy metabolism in rodents. Improved mitochondrial function and insulin sensitivity in obese humans. [6, 36, 99]
Antioxidant defense via Nrf2 pathway Upregulates HO-1, SOD, and catalase; reduces ROS and oxidative DNA damage in aging models. Limited but suggests reduced oxidative biomarkers in at-risk groups. [37, 100]
Anti-inflammatory effects (lowers NF-κB, cytokines) Suppresses pro-inflammatory cytokines (IL-6, TNF-α); delays vascular aging in rodents. Modest reductions in CRP and inflammatory markers in clinical trials. [40, 76, 101]
Metabolic health Improves glucose tolerance, lipid profile, and insulin signaling in rodents. Improved metabolic profile in obese adults, but no effect in NAFLD patients. [55, 97, 98]
Neuroprotection and cognitive aging Enhances synaptic plasticity, memory, and protects against neurodegeneration in animal models. Early studies show improved cerebral blood flow and memory in older adults. [6, 97, 102]

Neuroprotective potential

Resveratrol has attracted considerable interest for its ability to cross the blood–brain barrier and modulate stress-response pathways relevant to neurodegenerative disorders. Mechanistically, resveratrol activates SIRT1 and AMPK, enhancing mitochondrial biogenesis and redox homeostasis via PGC-1α/NRF1/NRF2 signaling [103]. It exerts potent antioxidant and anti-inflammatory effects, lowering reactive oxygen species, upregulating endogenous enzymes such as superoxide dismutase and catalase, and suppressing NF-κB–mediated cytokine release and microglial activation, thereby preserving neuronal function and blood–brain barrier integrity [104, 105].

Resveratrol also promotes autophagy and proteostasis, facilitating the clearance of amyloid-β, tau, and α-synuclein aggregates and damaged mitochondria, while modulating PI3K/Akt/mTOR and Wnt signaling to limit apoptosis [106, 107]. Preclinical models of Alzheimer’s disease and Parkinson’s disease consistently demonstrate reduced protein aggregation, preserved dopaminergic neurons, and improvements in cognitive and motor outcomes [107, 108].

Clinical translation, however, remains challenging. In a Phase II randomized, double-blind, placebo-controlled trial involving patients with mild-to-moderate Alzheimer’s disease, resveratrol (1 g twice daily for 52 w) was well tolerated and demonstrated biomarker engagement, including reduced CSF MMP9 levels and attenuated brain volume loss. However, the study failed to meet its primary cognitive endpoints, indicating that while resveratrol modulated molecular and imaging biomarkers, these effects did not translate into measurable clinical improvement [102]. In ischemic stroke models, resveratrol attenuates excitotoxicity, apoptosis, and blood–brain barrier disruption, resulting in smaller infarct size and better functional outcomes, largely via SIRT1/NRF2 activation [104, 105]. However, its low bioavailability and rapid metabolism remain major translational barriers, prompting exploration of nano formulations, liposomes, and prodrugs to enhance clinical efficacy [103]. Overall, while resveratrol exhibits promising neuroprotective mechanisms, clinical benefits have not yet been demonstrated, underscoring the need for large, well-controlled trials to bridge the gap between biomarker modulation and meaningful neurological improvement.

Antimicrobial and antiviral activity

In bacterial systems, resveratrol and its derivatives interfere with multiple cellular functions including disruption of cell wall integrity, inhibition of DNA and RNA synthesis, and suppression of quorum sensing, which collectively reduces bacterial growth and biofilm formation. These effects have been documented against diverse pathogens such as Staphylococcus aureus, Escherichia coli, and Helicobacter pylori, highlighting its relevance against both Gram-positive and Gram-negative organisms [66, 109]. In fungal pathogens such as Candida albicans and Aspergillus fumigatus, resveratrol and its derivatives has been shown to inhibit hyphal development, impair mitochondrial function, and trigger apoptotic cell death, thereby weakening fungal virulence and persistence [65, 110].

Resveratrol also demonstrates remarkable antiviral activity by targeting different stages of the viral life cycle and reinforcing host immune defenses. It has been reported to inhibit replication and gene expression of herpes simplex virus, suppress the replication of influenza virus, and reduce infectivity of hepatitis C virus [111–114]. More recently, in the context of coronaviruses, resveratrol was found to block SARS-CoV-2 replication by interfering with viral RNA polymerase activity and simultaneously reducing the virus-induced pro-inflammatory cytokine response, an effect that is particularly relevant to controlling hyper inflammation in severe cases [115]. Importantly, resveratrol has been shown to act synergistically with conventional antibiotics and antiviral agents, thereby enhancing therapeutic efficacy and reducing the likelihood of resistance development [65, 109].

Antidiabetic activity

Resveratrol has emerged as a promising natural compound for the management of diabetes mellitus due to its ability to modulate glucose homeostasis, insulin sensitivity, and β-cell function. One of the central mechanisms involves activation of AMP-activated protein kinase (AMPK) and SIRT1 pathways, which enhance mitochondrial biogenesis, promote fatty acid oxidation, and improve insulin signaling [6, 116]. Resveratrol also exerts potent antioxidant and anti-inflammatory effects, reducing oxidative stress and pro-inflammatory cytokine release in pancreatic islets, thereby preserving β-cell integrity [52, 54]. In animal models of type 2 diabetes (T2DM), resveratrol improves glucose tolerance, reduces insulin resistance, and protects against diabetic complications such as nephropathy and neuropathy [54].

Dose-dependent effects of resveratrol have been reported in both clinical and preclinical studies. In human trials, resveratrol doses ≥100 mg/d produced significantly greater reductions in fasting plasma glucose compared to lower doses (<100 mg/d). Doses of 300, 1000, and 1500 mg/d demonstrated the most favorable metabolic responses, including improved insulin sensitivity and reductions in HbA1c, whereas 8 mg and 50 mg/d produced minimal or no metabolic benefit [38, 52]. Interestingly, a recent meta-analysis of animal models of diabetic nephropathy revealed a U-shaped dose-response relationship, with optimal renoprotective effects observed at either lower doses (≤15 mg/kg/d) or higher doses (100–200 mg/kg/d) [117]. This suggests that both moderate and high dose regimens may confer therapeutic benefits, depending on the target tissue and specific metabolic endpoint. Collectively, resveratrol acts on multiple metabolic pathways, making it a valuable candidate for adjunct therapy in diabetes management.

Myths and facts about resveratrol

Several misconceptions surround resveratrol, often fueled by popular media. One common belief is that drinking red wine provides sufficient resveratrol for health benefits; however, wine contains only trace amounts (table 1), and achieving therapeutic levels would require impractically high consumption [20]. Another widespread myth is that resveratrol acts as a “miracle anti-aging pill” [118]. While preclinical and animal studies suggest potential longevity and health-promoting effects, evidence in humans remains inconclusive [6, 119–121]. Similarly, it is often assumed that all resveratrol supplements are equally effective, yet differences in formulation, purity, and bioavailability lead to significant variations in their efficacy [34]. Furthermore, resveratrol is sometimes promoted as a cancer cure; although it demonstrates anticancer activity in preclinical studies, it cannot be considered a stand-alone therapy [47, 122]. In summary, resveratrol holds promise as a bioactive compound with antioxidant, anti-inflammatory, and disease-modifying properties, but its benefits are frequently overstated. More rigorous and well-controlled human studies are necessary to clarify its therapeutic potential and establish its role as a supportive rather than curative agent.

Table 4: Common myths and facts about resveratrol. Summary of prevalent misconceptions and evidence-based findings illustrating that resveratrol’s biological effects are context-dependent and often overstated in popular media

Myth Fact Reference
Drinking red wine provides enough resveratrol for health benefits Red wine contains only trace amounts of resveratrol. Achieving the concentration used in experimental or clinical studies would require consuming unrealistically large and unsafe volumes of wine. Therefore, wine alone cannot provide meaningful physiological levels of resveratrol. [20, 31]
Resveratrol is a miracle anti-aging pill Although resveratrol has been shown to extend lifespan in simple organisms such as yeast, worms, silkworms and flies, its effects in mammals are inconsistent and relatively modest. There is no conclusive evidence that resveratrol prolongs lifespan in humans. Nonetheless, it may enhance cellular defense mechanisms and stress resistance, contributing to overall metabolic health. [6, 33, 119–121, 123]
All resveratrol supplements are equally effective The efficacy of resveratrol supplements varies significantly depending on formulation, purity, and bioavailability. Differences in absorption and metabolic stability determine how much active compound reaches target tissues, meaning not all products deliver the same biological effects. [34]
Resveratrol supplements are always safe In human clinical studies, resveratrol has been shown to be generally well-tolerated at doses up to approximately 0.5–1 g per day. However, higher doses, typically in the range of 2–5 g per day may lead to mild gastrointestinal discomfort in some individuals. Preclinical investigations have also revealed that resveratrol can interact with liver enzymes, particularly the cytochrome P450 system, which plays a key role in drug metabolism. This interaction suggests the need for caution when resveratrol is taken alongside medications that are metabolized through these pathways. [31, 99, 124–126]
Resveratrol can cure cancer While resveratrol exhibits anticancer properties in cell-based and animal studies, such as inhibiting tumor growth and inducing apoptosis, it is not a proven or standalone cancer therapy in humans. Clinical evidence remains insufficient to support its use as an anticancer drug. [47, 87, 122, 127]

CONCLUSION

Resveratrol stands out as a versatile natural compound with broad biological activities, including antioxidant, anti-inflammatory, cardioprotective, anticancer, neuroprotective, antimicrobial, and antidiabetic effects. Its pleiotropic mechanisms make it particularly relevant in addressing complex diseases driven by oxidative stress, inflammation, and metabolic dysfunction. While preclinical evidence is robust, human clinical outcomes remain inconsistent, largely due to its poor bioavailability and rapid metabolism. Recent advances in nanoparticle delivery, structural analogs, and synergistic formulations are promising steps toward overcoming these limitations. However, resveratrol should not be viewed as a miracle cure but rather as a valuable adjunct with potential to complement conventional therapies. Future progress will depend on well-designed, long-term clinical trials that clarify effective doses, safety, and therapeutic windows. Overall, resveratrol exemplifies the promise of natural molecules in modern medicine, serving as a bridge between traditional knowledge and translational science.

FUNDING

This work did not receive funding.

AUTHORS CONTRIBUTIONS

All authors have contributed equally

CONFLICT OF INTERESTS

The author confirms that there are no conflicts of interest related to this work.

REFERENCES

  1. Wang DG, Liu WY, Chen GT. A simple method for the isolation and purification of resveratrol from Polygonum cuspidatum. J Pharm Anal. 2013 Aug;3(4):241-7. doi: 10.1016/j.jpha.2012.12.001, PMID 29403824.

  2. Catalgol B, Batirel S, Taga Y, Ozer NK. Resveratrol: French paradox revisited. Front Pharmacol. 2012 Jul 17;3:141. doi: 10.3389/fphar.2012.00141, PMID 22822401.

  3. Orallo F. Comparative studies of the antioxidant effects of cis- and trans-resveratrol. Curr Med Chem. 2006;13(1):87-98. doi: 10.2174/092986706775197962, PMID 16457641.

  4. Thiel G, Rossler OG. Resveratrol regulates gene transcription via activation of stimulus-responsive transcription factors. Pharmacol Res. 2017 Mar;117:166-76. doi: 10.1016/j.phrs.2016.12.029, PMID 28012964.

  5. Fremont L. Biological effects of resveratrol. Life Sci. 2000 Jan;66(8):663-73. doi: 10.1016/S0024-3205(99)00410-5, PMID 10680575.

  6. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 2006 Jun 26;5(6):493-506. doi: 10.1038/nrd2060, PMID 16732220.

  7. Kulkarni SS, Canto C. The molecular targets of resveratrol. Biochim Biophys Acta. 2015 Jun;1852(6):1114-23. doi: 10.1016/j.bbadis.2014.10.005, PMID 25315298.

  8. Gulcin I. Antioxidant properties of resveratrol: a structure-activity insight. Innov Food Sci Emerg Technol. 2010 Jan;11(1):210-8. doi: 10.1016/j.ifset.2009.07.002.

  9. Walle T. Bioavailability of resveratrol. Ann NY Acad Sci. 2011 Jan 24;1215(1):9-15. doi: 10.1111/j.1749-6632.2010.05842.x, PMID 21261636.

  10. Chimento A, De Amicis F, Sirianni R, Sinicropi MS, Puoci F, Casaburi I. Progress to improve oral bioavailability and beneficial effects of resveratrol. Int J Mol Sci. 2019 Mar 19;20(6):1381. doi: 10.3390/ijms20061381, PMID 30893846.

  11. Amri A, Chaumeil JC, Sfar S, Charrueau C. Administration of resveratrol: what formulation solutions to bioavailability limitations? J Control Release. 2012 Mar;158(2):182-93. doi: 10.1016/j.jconrel.2011.09.083, PMID 21978644.

  12. Machado ND, Fernandez MA, Diaz DD. Recent strategies in resveratrol delivery systems. ChemPlusChem. 2019 Jul 10;84(7):951-73. doi: 10.1002/cplu.201900267, PMID 31943987.

  13. Najafiyan B, Bokaii Hosseini Z, Esmaelian S, Firuzpour F, Rahimipour Anaraki S, Kalantari L. Unveiling the potential effects of resveratrol in lung cancer treatment: mechanisms and nanoparticle-based drug delivery strategies. Biomed Pharmacother. 2024 Mar;172:116207. doi: 10.1016/j.biopha.2024.116207, PMID 38295754.

  14. Isailovic BD, Kostic IT, Zvonar A, Dordevic VB, Gasperlin M, Nedovic VA. Resveratrol-loaded liposomes produced by different techniques. Innov Food Sci Emerg Technol. 2013 Jul;19:181-9. doi: 10.1016/j.ifset.2013.03.006.

  15. Chen H, Tuck T, Ji X, Zhou X, Kelly G, Cuerrier A. Quality assessment of Japanese knotweed (Fallopia japonica) grown on Prince Edward Island as a source of resveratrol. J Agric Food Chem. 2013 Jul 3;61(26):6383-92. doi: 10.1021/jf4019239, PMID 23742076.

  16. Sales JM, Resurreccion AV. Resveratrol in peanuts. Crit Rev Food Sci Nutr. 2014 Jan 17;54(6):734-70. doi: 10.1080/10408398.2011.606928, PMID 24345046.

  17. Hasan M, Bae H. An overview of stress-induced resveratrol synthesis in grapes: perspectives for resveratrol-enriched grape products. Molecules. 2017 Feb 14;22(2):294. doi: 10.3390/molecules22020294, PMID 28216605.

  18. Hangun Balkir Y, McKenney ML. Determination of antioxidant activities of berries and resveratrol. Green Chem Lett Rev. 2012 Jun;5(2):147-53. doi: 10.1080/17518253.2011.603756.

  19. Aldred D, Cairns Fuller V, Magan N. Environmental factors affect efficacy of some essential oils and resveratrol to control growth and ochratoxin a production by Penicillium verrucosum and Aspergillus westerdijkiae on wheat grain. J Stored Prod Res. 2008;44(4):341-6. doi: 10.1016/j.jspr.2008.03.004.

  20. Geana EI, Dinca OR, Ionete RE, Artem V, Niculescu VC. Monitoring trans-resveratrol in grape berry skins during ripening and in corresponding wines by HPLC. Food Technol Biotechnol. 2015 Mar 30;53(1):73-80. doi: 10.17113/ftb.53.01.15.3762, PMID 27904334.

  21. Lachman J, Sulc M, Hejtmankova A, Pivec V, Orsak M. Content of polyphenolic antioxidants and trans-resveratrol in grapes of different varieties of grapevine (Vitis vinifera L.). Hortic Sci. 2004;31(2):63-9. doi: 10.17221/3794-HORTSCI.

  22. Taquichiri M, Ayarde R, Gutierrez P, Bustos AS, Paredes C, Callisaya JC. High levels of resveratrol in grapes cultivated at high altitude valleys in Bolivia. Int J Fruit Sci. 2014 Jul 3;14(3):311-26. doi: 10.1080/15538362.2013.819748.

  23. Hurst WJ, Glinski JA, Miller KB, Apgar J, Davey MH, Stuart DA. Survey of the trans-resveratrol and trans-piceid content of cocoa-containing and chocolate products. J Agric Food Chem. 2008 Sep 24;56(18):8374-8. doi: 10.1021/jf801297w, PMID 18759443.

  24. Paradiso A, D Amico L, Nicoletti I, Santino A, De Gara L, Giovinazzo G. Resveratrol biosynthesis up-regulates the ascorbate/glutathione pathway in transgenic tomato fruit. J Plant Biochem Physiol. 2013;1(2):2-7. doi: 10.4172/jpbp.1000105.

  25. Niu J, Hou Z, Ou Z, Hui W. Comparative study of effects of resveratrol, 1-MCP and DPA treatments on postharvest quality and superficial scald of ‘Starkrimson’ apples. Sci Hortic. 2018 Oct;240:516-21. doi: 10.1016/j.scienta.2018.06.037.

  26. Francini A, Sebastiani L. Phenolic compounds in apple (malus x domestica Borkh.): compounds characterization and stability during postharvest and after processing. Antioxidants (Basel). 2013 Sep 18;2(3):181-93. doi: 10.3390/antiox2030181, PMID 26784345.

  27. Xu Y, Fang M, Li X, Wang D, Yu L, Ma F. Contributions of common foods to resveratrol intake in the Chinese diet. Foods. 2024 Apr 21;13(8):1267. doi: 10.3390/foods13081267, PMID 38672939.

  28. Serra AT, Matias AA, Frade RF, Duarte RO, Feliciano RP, Bronze MR. Characterization of traditional and exotic apple varieties from Portugal. Part 2 – Antioxidant and antiproliferative activities. J Funct Foods. 2010 Jan;2(1):46-53. doi: 10.1016/j.jff.2009.12.005.

  29. Shrikanta A, Kumar A, Govindaswamy V. Resveratrol content and antioxidant properties of underutilized fruits. J Food Sci Technol. 2015 Jan;52(1):383-90. doi: 10.1007/s13197-013-0993-z, PMID 25593373.

  30. Kurita S, Kashiwagi T, Ebisu T, Shimamura T, Ukeda H. Content of resveratrol and glycoside and its contribution to the antioxidative capacity of Polygonum cuspidatum (Itadori) harvested in Kochi. Biosci Biotechnol Biochem. 2014 Mar 4;78(3):499-502. doi: 10.1080/09168451.2014.890032, PMID 25036841.

  31. Brown VA, Patel KR, Viskaduraki M, Crowell JA, Perloff M, Booth TD. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics and effect on the insulin-like growth factor axis. Cancer Res. 2010 Nov 15;70(22):9003-11. doi: 10.1158/0008-5472.CAN-10-2364, PMID 20935227.

  32. Chow HH, Garland LL, Hsu CH, Vining DR, Chew WM, Miller JA. Resveratrol modulates drug and carcinogen-metabolizing enzymes in a healthy volunteer study. Cancer Prev Res (Phila). 2010 Sep 1;3(9):1168-75. doi: 10.1158/1940-6207.CAPR-09-0155, PMID 20716633.

  33. Tome Carneiro J, Gonzalvez M, Larrosa M, Yanez Gascon MJ, Garcia Almagro FJ, Ruiz Ros JA. One-year consumption of a grape nutraceutical containing resveratrol improves the inflammatory and fibrinolytic status of patients in primary prevention of cardiovascular disease. Am J Cardiol. 2012 Aug;110(3):356-63. doi: 10.1016/j.amjcard.2012.03.030, PMID 22520621.

  34. Smoliga JM, Baur JA, Hausenblas HA. Resveratrol and health a comprehensive review of Human Clinical Trials. Mol Nutr Food Res. 2011 Aug 20;55(8):1129-41. doi: 10.1002/mnfr.201100143, PMID 21688389.

  35. Pangeni R, Sahni JK, Ali J, Sharma S, Baboota S. Resveratrol: review on therapeutic potential and recent advances in drug delivery. Expert Opin Drug Deliv. 2014 Aug 15;11(8):1285-98. doi: 10.1517/17425247.2014.919253, PMID 24830814.

  36. Price NL, Gomes AP, Ling AJ, Duarte FV, Martin Montalvo A, North BJ. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab. 2012 May;15(5):675-90. doi: 10.1016/j.cmet.2012.04.003, PMID 22560220.

  37. Pouremamali F, Pouremamali A, Dadashpour M, Soozangar N, Jeddi F. An update of Nrf2 activators and inhibitors in cancer prevention/promotion. Cell Commun Signal. 2022 Dec 30;20(1):100. doi: 10.1186/s12964-022-00906-3, PMID 35773670.

  38. Movahed A, Nabipour I, Lieben Louis X, Thandapilly SJ, Yu L, Kalantarhormozi M. Antihyperglycemic effects of short-term resveratrol supplementation in type 2 diabetic patients. Evid Based Complement Alternat Med. 2013;2013:851267. doi: 10.1155/2013/851267, PMID 24073011.

  39. Zhou DD, Luo M, Huang SY, Saimaiti A, Shang A, Gan RY. Effects and mechanisms of resveratrol on aging and age-related diseases. Oxid Med Cell Longev. 2021 Jan 12;2021(1):9932218. doi: 10.1155/2021/9932218, PMID 34336123.

  40. Csiszar A. Anti‐inflammatory effects of resveratrol: possible role in prevention of age-related cardiovascular disease. Ann NY Acad Sci. 2011 Jan 24;1215(1):117-22. doi: 10.1111/j.1749-6632.2010.05848.x, PMID 21261649.

  41. Meng T, Xiao D, Muhammed A, Deng J, Chen L, He J. Anti-inflammatory action and mechanisms of resveratrol. Molecules. 2021 Jan 5;26(1):229. doi: 10.3390/molecules26010229, PMID 33466247.

  42. Ma C, Wang Y, Dong L, Li M, Cai W. Anti-inflammatory effect of resveratrol through the suppression of NF-κB and JAK/STAT signaling pathways. Acta Biochim Biophys Sin (Shanghai). 2015 Mar 1;47(3):207-13. doi: 10.1093/abbs/gmu135, PMID 25651848.

  43. Dolinsky VW, Chakrabarti S, Pereira TJ, Oka T, Levasseur J, Beker D. Resveratrol prevents hypertension and cardiac hypertrophy in hypertensive rats and mice. Biochim Biophys Acta. 2013 Oct;1832(10):1723-33. doi: 10.1016/j.bbadis.2013.05.018, PMID 23707558.

  44. Simental Mendia LE, Guerrero Romero F. Effect of resveratrol supplementation on lipid profile in subjects with dyslipidemia: a randomized double-blind placebo-controlled trial. Nutrition. 2019 Feb;58:7-10. doi: 10.1016/j.nut.2018.06.015, PMID 30278430.

  45. Xia N, Forstermann U, Li H. Resveratrol and endothelial nitric oxide. Molecules. 2014 Oct 9;19(10):16102-21. doi: 10.3390/molecules191016102, PMID 25302702.

  46. Ojha R, Pranesh K, Bhavin V. Randomized active controlled clinical study to evaluate efficacy and safety of resveratrol as an adjuvant therapy in patients with hypertension. Asian J Pharm Clin Res. 2016 Jan 1;10(1):376. doi: 10.22159/ajpcr.2017.v10i1.15603.

  47. Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S, Takada Y. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res. 2004;24(5A):2783-840. PMID 15517885.

  48. Athar M, Back JH, Kopelovich L, Bickers DR, Kim AL. Multiple molecular targets of resveratrol: anti-carcinogenic mechanisms. Arch Biochem Biophys. 2009 Jun;486(2):95-102. doi: 10.1016/j.abb.2009.01.018, PMID 19514131.

  49. Xie Y, Wang Y, Xiang W, Wang Q, Cao Y. Molecular mechanisms of the action of myricetin in cancer. Mini Rev Med Chem. 2020;20(2):123-33. doi: 10.2174/1389557519666191018112756, PMID 31648635.

  50. Thongsom S, Racha S, Petsri K, Ei ZZ, Visuttijai K, Moriue S. Structural modification of resveratrol analogue exhibits anticancer activity against lung cancer stem cells via suppression of Akt signaling pathway. BMC Complement Med Ther. 2023 Jun 3;23(1):183. doi: 10.1186/s12906-023-04016-6, PMID 37270520.

  51. Innets B, Thongsom S, Petsri K, Racha S, Yokoya M, Moriue S. Akt/mTOR targeting activity of resveratrol derivatives in non-small lung cancer. Molecules. 2022 Nov 27;27(23):8268. doi: 10.3390/molecules27238268, PMID 36500361.

  52. Brasnyo P, Molnar GA, Mohas M, Marko L, Laczy B, Cseh J. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br J Nutr. 2011 Aug;106(3):383-9. doi: 10.1017/S0007114511000316, PMID 21385509.

  53. Zhu P, Jin Y, Sun J, Zhou X. The efficacy of resveratrol supplementation on inflammation and oxidative stress in type-2 diabetes mellitus patients: randomized double-blind placebo meta-analysis. Front Endocrinol (Lausanne). 2025 Jan 13;15:1463027. doi: 10.3389/fendo.2024.1463027, PMID 39872318.

  54. Szkudelski T, Szkudelska K. Resveratrol and diabetes: from animal to human studies. Biochim Biophys Acta. 2015 Jun;1852(6):1145-54. doi: 10.1016/j.bbadis.2014.10.013, PMID 25445538.

  55. Chachay VS, Macdonald GA, Martin JH, Whitehead JP, O Moore Sullivan TM, Lee P. Resveratrol does not benefit patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014 Dec;12(12):2092-103.e1. doi: 10.1016/j.cgh.2014.02.024, PMID 24582567.

  56. Tejada S, Capo X, Mascaro CM, Monserrat Mesquida M, Quetglas Llabres MM, Pons A. Hepatoprotective effects of resveratrol in non-alcoholic fatty live disease. Curr Pharm Des. 2021 Sep 1;27(22):2558-70. doi: 10.2174/1381612826666200417165801, PMID 32303170.

  57. Jia R, Li Y, Cao L, Du J, Zheng T, Qian H. Antioxidative anti-inflammatory and hepatoprotective effects of resveratrol on oxidative stress-induced liver damage in tilapia (Oreochromis niloticus). Comp Biochem Physiol C Toxicol Pharmacol. 2019 Jan;215:56-66. doi: 10.1016/j.cbpc.2018.10.002, PMID 30336289.

  58. Gezer A, Ustundag H, Mendil AS, Bedir G, Duysak L. Hepatoprotective effects of resveratrol on α-amanitin-induced liver toxicity in rats. Toxicon. 2024 Aug;247:107855. doi: 10.1016/j.toxicon.2024.107855, PMID 38996975.

  59. Albani D, Polito L, Signorini A, Forloni G. Neuroprotective properties of resveratrol in different neurodegenerative disorders. BioFactors. 2010 Sep 16;36(5):370-6. doi: 10.1002/biof.118, PMID 20848560.

  60. Bastianetto S, Menard C, Quirion R. Neuroprotective action of resveratrol. Biochim Biophys Acta. 2015 Jun;1852(6):1195-201. doi: 10.1016/j.bbadis.2014.09.011, PMID 25281824.

  61. Tresguerres IF, Tamimi F, Eimar H, Barralet J, Torres J, Blanco L. Resveratrol as anti-aging therapy for age-related bone loss. Rejuvenation Res. 2014 Oct;17(5):439-45. doi: 10.1089/rej.2014.1551, PMID 24956408.

  62. De La Lastra CA, Villegas I. Resveratrol as an anti-inflammatory and anti-aging agent: mechanisms and clinical implications. Mol Nutr Food Res. 2005 May;49(5):405-30. doi: 10.1002/mnfr.200500022, PMID 15832402.

  63. Wang W, Zhang LM, Guo C, Han JF. Resveratrol promotes osteoblastic differentiation in a rat model of postmenopausal osteoporosis by regulating autophagy. Nutr Metab (Lond). 2020 Dec 16;17(1):29. doi: 10.1186/s12986-020-00449-9, PMID 32322287.

  64. Li Q, Yang G, Xu H, Tang S, Lee WY. Effects of resveratrol supplementation on bone quality: a systematic review and meta-analysis of randomized controlled trials. BMC Complement Med Ther. 2021 Dec 22;21(1):214. doi: 10.1186/s12906-021-03381-4, PMID 34420523.

  65. Vestergaard M, Ingmer H. Antibacterial and antifungal properties of resveratrol. Int J Antimicrob Agents. 2019 Jun;53(6):716-23. doi: 10.1016/j.ijantimicag.2019.02.015, PMID 30825504.

  66. Karamese M, Dicle Y. The antibacterial and antibiofilm activities of resveratrol on gram-positive and gram-negative bacteria. Kafkas J Med Sci. 2022;12(3):201-6. doi: 10.5505/kjms.2022.76743.

  67. Ratz Lyko A, Arct J. Resveratrol as an active ingredient for cosmetic and dermatological applications: a review. J Cosmet Laser Ther. 2019 Feb 17;21(2):84-90. doi: 10.1080/14764172.2018.1469767, PMID 29737899.

  68. Mascarenhas Melo F, Araujo A, Rodrigues M, Mathur A, Goncalves M, Tanwar K. Dermatological bioactivities of resveratrol and nanotechnology strategies to boost its efficacy an updated review. Cosmetics. 2023 Apr 24;10(3):68. doi: 10.3390/cosmetics10030068.

  69. Kitada M, Koya D. Renal protective effects of resveratrol. Oxid Med Cell Longev. 2013;2013:568093. doi: 10.1155/2013/568093, PMID 24379901.

  70. Dos Santos AB, Santos Terra J, Carletti JV, Deckmann I, Gottfried C. Molecular alterations in ferroptosis and the effects of resveratrol: a systematic review. J Biochem Mol Toxicol. 2025 Jul 30;39(7):e70384. doi: 10.1002/jbt.70384, PMID 40586281.

  71. Murcia MA, Martinez Tome M. Antioxidant activity of resveratrol compared with common food additives. J Food Prot. 2001 Mar;64(3):379-84. doi: 10.4315/0362-028X-64.3.379, PMID 11252483.

  72. Martins LA, Coelho BP, Behr G, Pettenuzzo LF, Souza IC, Moreira JC. Resveratrol induces pro-oxidant effects and time-dependent resistance to cytotoxicity in activated hepatic stellate cells. Cell Biochem Biophys. 2014 Mar 21;68(2):247-57. doi: 10.1007/s12013-013-9703-8, PMID 23793960.

  73. Zhang J, Fu Q, Wang Y, Mu Y, Ren H, Xue L. Resveratrol alleviates oxidative stress, inflammatory cytokine expression and apoptosis induced by nanoplastics in the hemocytes of abalone (Haliotis discus hannai). Aquac rep. Aquacult Rep. 2025 Sep;43:102983. doi: 10.1016/j.aqrep.2025.102983.

  74. Yang M, Shen Y, Zhao S, Zhang R, Dong W, Lei X. Protective effect of resveratrol on mitochondrial biogenesis during hyperoxia-induced brain injury in neonatal pups. BMC Neurosci. 2023 Apr 25;24(1):27. doi: 10.1186/s12868-023-00797-1, PMID 37098490.

  75. Wu SK, Wang L, Wang F, Zhang J. Resveratrol improved mitochondrial biogenesis by activating SIRT1/PGC-1α signal pathway in SAP. Sci Rep. 2024 Oct 31;14(1):26216. doi: 10.1038/s41598-024-76825-9, PMID 39482340.

  76. Shaito A, Al Mansoob M, Ahmad SM, Haider MZ, Eid AH, Posadino AM. Resveratrol mediated regulation of mitochondria biogenesis associated pathways in neurodegenerative diseases: molecular insights and potential therapeutic applications. Curr Neuropharmacol. 2023 May;21(5):1184-201. doi: 10.2174/1570159X20666221012122855, PMID 36237161.

  77. Brown K, Theofanous D, Britton RG, Aburido G, Pepper C, Sri Undru S. Resveratrol for the management of human health: how far have we come? A systematic review of resveratrol clinical trials to highlight gaps and opportunities. Int J Mol Sci. 2024 Jan 6;25(2):747. doi: 10.3390/ijms25020747, PMID 38255828.

  78. Li J, Koonyosying P, Korsieporn W, Paradee N, Hutachok N, Xu H. Deferiprone resveratrol hybrid attenuates iron accumulation oxidative stress and antioxidant defenses in iron-loaded human Huh7 hepatic cells. Front Mol Biosci. 2024 Mar 20;11:1364261. doi: 10.3389/fmolb.2024.1364261, PMID 38572444.

  79. Kontoghiorghes GJ. New approaches and strategies for the repurposing of iron chelating/antioxidant drugs for diseases of free radical pathology in medicine. Antioxidants (Basel). 2025 Aug 10;14(8):982. doi: 10.3390/antiox14080982, PMID 40867878.

  80. Pal K, Raghuram GV, Dsouza J, Shinde S, Jadhav V, Shaikh A. A pro-oxidant combination of resveratrol and copper down-regulates multiple biological hallmarks of ageing and neurodegeneration in mice. Sci Rep. 2022 Oct 14;12(1):17209. doi: 10.1038/s41598-022-21388-w, PMID 36241685.

  81. Ahmad A, Syed FA, Singh S, Hadi SM. Prooxidant activity of resveratrol in the presence of copper ions: mutagenicity in plasmid DNA. Toxicol Lett. 2005 Oct;159(1):1-12. doi: 10.1016/j.toxlet.2005.04.001, PMID 15913925.

  82. Farhan M, Rizvi A. Understanding the prooxidant action of plant polyphenols in the cellular microenvironment of malignant cells: role of copper and therapeutic implications. Front Pharmacol. 2022 Jun 20;13:929853. doi: 10.3389/fphar.2022.929853, PMID 35795551.

  83. Gu XS, Wang ZB, Ye Z, Lei JP, Li L, Su DF. Resveratrol an activator of SIRT1, upregulates AMPK and improves cardiac function in heart failure. Genet Mol Res. 2014;13(1):323-35. doi: 10.4238/2014.January.17.17, PMID 24535859.

  84. Bonnefont Rousselot D. Resveratrol and cardiovascular diseases. Nutrients. 2016 May 2;8(5):250. doi: 10.3390/nu8050250, PMID 27144581.

  85. Bagul PK, Deepthi N, Sultana R, Banerjee SK. Resveratrol ameliorates cardiac oxidative stress in diabetes through deacetylation of NFkB-p65 and histone 3. J Nutr Biochem. 2015 Nov;26(11):1298-307. doi: 10.1016/j.jnutbio.2015.06.006, PMID 26298192.

  86. Dyck GJ, Raj P, Zieroth S, Dyck JR, Ezekowitz JA. The effects of resveratrol in patients with cardiovascular disease and heart failure: a narrative review. Int J Mol Sci. 2019 Feb 19;20(4):904. doi: 10.3390/ijms20040904, PMID 30791450.

  87. Ko JH, Sethi G, Um JY, Shanmugam MK, Arfuso F, Kumar AP. The role of resveratrol in cancer therapy. Int J Mol Sci. 2017 Dec 1;18(12):2589. doi: 10.3390/ijms18122589, PMID 29194365.

  88. Yang Q, Meng D, Zhang Q, Wang J. Advances in the role of resveratrol and its mechanism of action in common gynecological tumors. Front Pharmacol. 2024 Jul 17;15:1417532. doi: 10.3389/fphar.2024.1417532, PMID 39086397.

  89. Song B, Wang W, Tang X, Goh RM, Thuya WL, Ho PC. Inhibitory potential of resveratrol in cancer metastasis: from biology to therapy. Cancers (Basel). 2023 May 14;15(10):2758. doi: 10.3390/cancers15102758, PMID 37345095.

  90. Ferraresi A, Thongchot S, Isidoro C. Resveratrol promotes self-digestion to put cancer to sleep. J Cancer Prev. 2024 Mar 30;29(1):1-5. doi: 10.15430/JCP.24.001, PMID 38567110.

  91. Brown VA, Patel KR, Viskaduraki M, Crowell JA, Perloff M, Booth TD. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics and effect on the insulin-like growth factor axis. Cancer Res. 2010 Nov 15;70(22):9003-11. doi: 10.1158/0008-5472.CAN-10-2364, PMID 20935227.

  92. Patel KR, Brown VA, Jones DJ, Britton RG, Hemingway D, Miller AS. Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res. 2010 Oct 1;70(19):7392-9. doi: 10.1158/0008-5472.CAN-10-2027, PMID 20841478.

  93. Xiao X, Wu X, Li W, You F, Guo J. Therapeutic effects and safety of resveratrol for lung cancer: an updated preclinical systematic review and meta-analysis. Front Nutr. 2025 Aug 29;12:1644538. doi: 10.3389/fnut.2025.1644538, PMID 40948874.

  94. Varoni EM, Lo Faro AF, Sharifi Rad J, Iriti M. Anticancer molecular mechanisms of resveratrol. Front Nutr. 2016 Apr 12;3:8. doi: 10.3389/fnut.2016.00008, PMID 27148534.

  95. Kohandel Z, Darrudi M, Naseri K, Samini F, Aschner M, Pourbagher Shahri AM. The role of resveratrol in aging and senescence: a focus on molecular mechanisms. Curr Mol Med. 2024 Jul;24(7):867-75. doi: 10.2174/1566524023666230602162949, PMID 37278035.

  96. Kim EN, Lim JH, Kim MY, Ban TH, Jang IA, Yoon HE. Resveratrol an Nrf2 activator ameliorates aging-related progressive renal injury. Aging. 2018 Jan 11;10(1):83-99. doi: 10.18632/aging.101361, PMID 29326403.

  97. Novelle MG, Wahl D, Dieguez C, Bernier M, De Cabo R. Resveratrol supplementation: where are we now and where should we go? Ageing Res Rev. 2015 May;21:1-15. doi: 10.1016/j.arr.2015.01.002, PMID 25625901.

  98. Timmers S, Konings E, Bilet L, Houtkooper RH, Van De Weijer T, Goossens GH. Calorie restriction-like effects of 30 d of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 2011 Nov;14(5):612-22. doi: 10.1016/j.cmet.2011.10.002, PMID 22055504.

  99. De Ligt M, Bruls YM, Hansen J, Habets MF, Havekes B, Nascimento EB. Resveratrol improves ex vivo mitochondrial function but does not affect insulin sensitivity or brown adipose tissue in first-degree relatives of patients with type 2 diabetes. Mol Metab. 2018 Jun;12:39-47. doi: 10.1016/j.molmet.2018.04.004, PMID 29706321.

  100. Franco FN, Arrieta OA, De Mello Silva B, Aragao MM, Nagem RA, De Araujo GR. Nrf2 cell signaling pathway is responsible for the antioxidant effect of resveratrol in aging. Geriatr Gerontol Int. 2024 Sep 8;24(9):954-61. doi: 10.1111/ggi.14939, PMID 39118439.

  101. Alesci A, Nicosia N, Fumia A, Giorgianni F, Santini A, Cicero N. Resveratrol and immune cells: a link to improve human health. Molecules. 2022 Jan 10;27(2):424. doi: 10.3390/molecules27020424, PMID 35056739.

  102. Turner RS, Thomas RG, Craft S, Van Dyck CH, Mintzer J, Reynolds BA. A randomized double-blind placebo-controlled trial of resveratrol for Alzheimer disease. Neurology. 2015 Oct 20;85(16):1383-91. doi: 10.1212/WNL.0000000000002035, PMID 26362286.

  103. Lopez MS, Dempsey RJ, Vemuganti R. Resveratrol neuroprotection in stroke and traumatic CNS injury. Neurochem Int. 2015 Oct;89:75-82. doi: 10.1016/j.neuint.2015.08.009, PMID 26277384.

  104. Shin JA, Lee H, Lim YK, Koh Y, Choi JH, Park EM. Therapeutic effects of resveratrol during acute periods following experimental ischemic stroke. J Neuroimmunol. 2010 Oct;227(1-2):93-100. doi: 10.1016/j.jneuroim.2010.06.017, PMID 20655115.

  105. Komorowska J, Wątroba M, Bednarzak M, Grabowska AD, Szukiewicz D. Anti-inflammatory action of resveratrol in the central nervous system in relation to glucose concentration-an in vitro study on a blood–brain barrier model. Int J Mol Sci. 2024 Mar 7;25(6):3110. doi: 10.3390/ijms25063110, PMID 38542084.

  106. Mathew LS, Marathe A, Aman A, Vats A, Joy T, Rao YL. Bridging the molecular and clinical aspects of resveratrol in Alzheimer’s disease: a review. 3 Biotech. 2025 Sep 6;15(9):284. doi: 10.1007/s13205-025-04451-x, PMID 40777747.

  107. Su CF, Jiang L, Zhang XW, Iyaswamy A, Li M. Resveratrol in rodent models of Parkinson’s disease: a systematic review of experimental studies. Front Pharmacol. 2021 Apr 22;12:644219. doi: 10.3389/fphar.2021.644219, PMID 33967780.

  108. Zhang F, Shi JS, Zhou H, Wilson B, Hong JS, Gao HM. Resveratrol protects dopamine neurons against lipopolysaccharide-induced neurotoxicity through its anti-inflammatory actions. Mol Pharmacol. 2010 Sep;78(3):466-77. doi: 10.1124/mol.110.064535, PMID 20554604.

  109. Cebrian R, Li Q, Penalver P, Belmonte Reche E, Andres Bilbao M, Lucas R. Chemically tuning resveratrol for the effective killing of gram-positive pathogens. J Nat Prod. 2022 Jun 24;85(6):1459-73. doi: 10.1021/acs.jnatprod.1c01107, PMID 35621995.

  110. Houille B, Papon N, Boudesocque L, Bourdeaud E, Besseau S, Courdavault V. Antifungal activity of resveratrol derivatives against candida species. J Nat Prod. 2014 Jul 25;77(7):1658-62. doi: 10.1021/np5002576, PMID 25014026.

  111. Docherty JJ, Fu MM, Stiffler BS, Limperos RJ, Pokabla CM, De Lucia AL. Resveratrol inhibition of herpes simplex virus replication. Antiviral Res. 1999 Oct;43(3):145-55. doi: 10.1016/S0166-3542(99)00042-X, PMID 10551373.

  112. Annunziata G, Maisto M, Schisano C, Ciampaglia R, Narciso V, Tenore GC. Resveratrol as a novel anti-herpes simplex virus nutraceutical agent: an overview. Viruses. 2018 Sep 3;10(9):473. doi: 10.3390/v10090473, PMID 30177661.

  113. Palamara AT, Nencioni L, Aquilano K, De Chiara G, Hernandez L, Cozzolino F. Inhibition of influenza a virus replication by resveratrol. J Infect Dis. 2005 May 15;191(10):1719-29. doi: 10.1086/429694, PMID 15838800.

  114. Lee S, Yoon KD, Lee M, Cho Y, Choi G, Jang H. Identification of a resveratrol tetramer as a potent inhibitor of hepatitis C virus helicase. Br J Pharmacol. 2016 Jan 25;173(1):191-211. doi: 10.1111/bph.13358, PMID 26445091.

  115. Van Brummelen R, Van Brummelen AC. The potential role of resveratrol as supportive antiviral in treating conditions such as COVID-19 a formulator’s perspective. Biomed Pharmacother. 2022 Apr;148:112767. doi: 10.1016/j.biopha.2022.112767, PMID 35240527.

  116. Lagouge M, Argmann C, Gerhart Hines Z, Meziane H, Lerin C, Daussin F. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell. 2006 Dec 15;127(6):1109-22. doi: 10.1016/j.cell.2006.11.013, PMID 17112576.

  117. Liu X, Gu X, Zhang J, Li X, Wei X, Jiang S. Resveratrol delays the progression of diabetic nephropathy through multiple pathways: a dose-response meta-analysis based on animal models. J Diabetes. 2024 Sep 12;16(9):e13608. doi: 10.1111/1753-0407.13608, PMID 39264004.

  118. Camins A, Junyent F, Verdaguer E, Beas Zarate C, Rojas Mayorquin AE, Ortuno-Sahagun D. Resveratrol: an antiaging drug with potential therapeutic applications in treating diseases. Pharmaceuticals (Basel). 2009 Dec 15;2(3):194-205. doi: 10.3390/ph2030194, PMID 27713233.

  119. Hector KL, Lagisz M, Nakagawa S. The effect of resveratrol on longevity across species: a meta-analysis. Biol Lett. 2012 Oct 23;8(5):790-3. doi: 10.1098/rsbl.2012.0316, PMID 22718956.

  120. Pallauf K, Rimbach G, Rupp PM, Chin D, Wolf IM. Resveratrol and lifespan in model organisms. Curr Med Chem. 2016 Dec 23;23(41):4639-80. doi: 10.2174/0929867323666161024151233, PMID 27781945.

  121. Song J, Liu L, Hao K, Mao S, Tang Y, Tong X. Resveratrol elongates the lifespan and improves antioxidant activity in the silkworm Bombyx mori. J Pharm Anal. 2021 Jun;11(3):374-82. doi: 10.1016/j.jpha.2020.06.005, PMID 34277125.

  122. Potter GA, Patterson LH, Wanogho E, Perry PJ, Butler PC, Ijaz T. The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1. Br J Cancer. 2002 Mar 26;86(5):774-8. doi: 10.1038/sj.bjc.6600197, PMID 11875742.

  123. Gambini J, Ingles M, Olaso G, Lopez Grueso R, Bonet Costa V, Gimeno Mallench L. Properties of resveratrol: in vitro and in vivo studies about metabolism, bioavailability and biological effects in animal models and humans. Oxid Med Cell Longev. 2015;2015:837042. doi: 10.1155/2015/837042, PMID 26221416.